GNG2 encodes the G protein gamma 2 subunit, which forms heterotrimeric G protein complexes essential for transmembrane signaling systems 1. As part of the Gβγ-dimer, GNG2 is required for GTPase activity, GDP-to-GTP exchange, and G protein-effector interactions in G protein-coupled receptor signaling pathways 1. GNG2 demonstrates tissue-specific expression patterns, being found in fetal tissues, adult testis, adrenal gland, brain, white blood cells, and lung 1. The protein serves as a neuroanatomical marker, with expression in the claustrum and insular cortex but not putamen, suggesting shared developmental origins of these brain regions 2. Disease relevance includes significantly altered expression in multiple conditions: reduced levels in malignant melanomas compared to benign tumors 3, downregulation in breast cancer where it acts as a tumor suppressor by interacting with MRAS to inhibit ERK and Akt signaling 4, differential expression in vasovagal syncope patients 5, and association with bipolar disorder pathways 6. Clinically, GNG2 represents a potential biomarker for melanoma progression and a therapeutic target in breast cancer, while also contributing to neuropsychiatric disorder pathogenesis through dysregulated G protein signaling networks.